Select Page

WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) — Rigrodsky & Long, P.A. announces that it is investigating MyoKardia, Inc. (“MyoKardia”) (NASDAQ GS: MYOK) regarding possible breaches of fiduciary duties and other violations of law related to MyoKardia’s agreement to be acquired by Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY). Under the terms of the agreement, MyoKardia’s shareholders will receive $225.00 in cash per share.